Patents Assigned to SIMCERE PHARMACEUTICAL CO., LTD.
  • Use of composition in treatment of cerebral stroke
    Patent number: 12629353
    Abstract: Use of a composition in preparation of a drug for treating a patient suffering from a cerebral stroke. The composition includes edaravone and dexborneol, and the patient has a history of hypertension.
    Type: Grant
    Filed: July 7, 2021
    Date of Patent: May 19, 2026
    Assignees: SIMCERE PHARMACEUTICAL CO., LTD., JIANGSU SIMCERE PHARMACEUTICAL CO., LTD
    Inventors: Xiaofei Feng, Shunwei Zhu, Cuncun Liu, Feng Wang, Jinsheng Ren
  • Pyrrolidine compound and use thereof
    Patent number: 12570652
    Abstract: Disclosed are a pyrrolidine compound as represented by formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and the use of the pharmaceutical composition as a selective estrogen receptor degrader (SERD) in the prevention or treatment of estrogen receptor-related diseases.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: March 10, 2026
    Assignees: SIMCERE PHARMACEUTICAL CO., LTD., JIANGSU SIMCERE PHARMACEUTICAL CO., LTD.
    Inventors: Peng Gu, Lei Liu, Guobao Zhang, Feng Zhou, Renhong Tang, Jinsheng Ren
  • COMPOUND AND USE THEREOF IN PREVENTING OR TREATING RADIATION DAMAGE
    Publication number: 20250345318
    Abstract: The present invention provides a compound and use thereof, particularly a JWA gene agonist and use thereof in preventing or treating radiation damage. The compound, by means of activating JWA gene expression, enhances the DNA repair capacity of cells, and has a good elimination capacity for highly active oxygen species generated by X-ray radiation. The compound can also effectively inhibit cell apoptosis caused by radiation to reduce the damage, and further reduce the generation of free radicals to reduce the probability of radiation damage.
    Type: Application
    Filed: May 25, 2023
    Publication date: November 13, 2025
    Applicants: SIMCERE PHARMACEUTICAL CO., LTD., JIANGSU SIMCERE PHARMACEUTICAL CO., LTD.
    Inventors: Jianwei Zhou, Yan Zhou, Jingwen Liu, Xiong Li, Aiping Li, Feng Tang, Lirong Hu, Yuxi Yan, Tengfei Xue, Yinqiang Zhuang, Yuanbin Hao
  • Antitumor compound for activating gene and degrading HER2, preparation method thereof, and application thereof
    Patent number: 11427575
    Abstract: A compound as shown in formula I. R1 is selected from the group consisting of —OH, —CH3, —CH2CH3, —OCH3, —OCH2CH3; R2 is selected from the group consisting of —H, —OH, —CH3, —CH2CH3, —CH2CH2CH3, —OCH3, —OCH2CH2CH3; R3 is selected from the group consisting of —F, —Cl, —Br, —I, —CF3; R4 is selected from the group consisting of —H, —F, —Cl, —Br, —I, —CF3; and R5 is selected from the group consisting of —H, —CH3, —CH2CH3.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: August 30, 2022
    Assignee: SIMCERE PHARMACEUTICAL CO., LTD.
    Inventor: Jianwei Zhou
  • Sublingual pharmaceutical compositions of edaravone and (+)-2-borneol
    Patent number: 11135199
    Abstract: A sublingual tablet pharmaceutical composition containing edaravone and (+)-2-borneol, and a preparation method thereof. The sublingual tablet pharmaceutical composition includes edaravone, (+)-2-camphanol, an excipient, a filler, a binder, a disintegrant, and a lubricant. The excipient is selected from one or more of mannitol, lactose, dextran, cysteine, glycine, copovidone, and beta-cyclodextrin.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: October 5, 2021
    Assignees: NEURODAWN PHARMACEUTICAL CO., LTD., SIMCERE PHARMACEUTICAL CO., LTD.
    Inventor: Yijun Wang